(Reuters) - Sucampo, which is not listed, and Takeda, Japan's biggest
drugmaker, co-market the drug in the United States.
The filing is for a lower strength version of Amitiza, which
is known generically as lubiprostone.
Read more at Reuters.com Government Filings News
drugmaker, co-market the drug in the United States.
The filing is for a lower strength version of Amitiza, which
is known generically as lubiprostone.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment